3C Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 29 Days
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 263.99%
- Profit Growth 6.21%
- Ebitda 10.03%
- Net Worth -68.31%
- Total Assets 65.92%
About 3C Pharmaceuticals
3C Pharmaceuticals Private Limited (3PPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 January 2016 (Nine years 29 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Srinivas Madineni, Vijaya Devareddy, Lella Pramodhini, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52100TG2016PTC102897
- Company No.
102897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jan 2016
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at 3C Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivas Madineni  | Director | 01-Sep-2017 | Current |
| Vijaya Devareddy | Director | 01-Sep-2017 | Current |
| Lella Pramodhini | Director | 29-Sep-2020 | Current |
| Srinivasa Patil | Director | 27-Jan-2016 | Current |
Financial Performance of 3C Pharmaceuticals.
3C Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 263.99% increase. The company also saw a slight improvement in profitability, with a 6.21% increase in profit. The company's net worth observed a substantial decline by a decrease of 68.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of 3C Pharmaceuticals?
In 2019, 3C Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at 3C Pharmaceuticals?
3C Pharmaceuticals has a workforce of 28 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of 3C Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped 3C Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
